LLY Research Update — May 1, 2026
Updated Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat supported by strong management under CEO David A.
The investment grade as of this refresh is B — solid business quality. High-tier business, mid-tier valuation
Key Metrics at a Glance
- Revenue growth: +55.5% year over year
- Net margin: 35.0%
- Forward P/E: 33.1x
- Fair value upside: +98.6% to our estimate of $1856
Current price: $934.34
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Eli Lilly and Company remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full LLY research →](/stocks/LLY)